It was a very positive event. It appears the management - knows what they are doing - expects a good HCC presentation at this year ASCO - was able to complete on time the enrollment of the PhIII NSCLC trial in spite of a competition for NSCLC patients from other companies - expects to file for the targeted NSCLC indication sometime late in 2013 - feels good about PhI results for a mutated-melanoma indication
The ASCO 2012 is next.
PS Marty, sorry to miss you at the meeting. At the end, everybody left very fast.
Yes, very positive meeting. Paolo made a point that for the first time in the company's history an Arqule compound (tivantinib) had achieved positive results as a monotherapy (in HCC). As pharma noted he alluded that very good detailed results would be presented at ASCO. The other point is that being able to enroll 1000 patients in the Marquee trial indicated an increasing awareness among oncologists of tivantinib. The poster displayed upon entering the meeting area stated ARQ197 is now tivantinib.
Pharma were you sitting to the left of the fellow with all the questions?